Skip to main content
. Author manuscript; available in PMC: 2015 Mar 24.
Published in final edited form as: Cancer. 2011 Mar 31;117(20):4679–4688. doi: 10.1002/cncr.26091

Figure 3.

Figure 3

Current progression-free survival (PFS) rate of 86 chronic lymphocytic leukemia patients who underwent nonmyeloablative stem cell transplantation is shown according to human leukocyte antigen (HLA) subtype. Patients who were HLA-A1 positive, HLA-A2 negative, and HLA-B44 negative had higher current PFS rates than did other patients who had 0, 1, or only 2 of these HLA factors.